Angiogenesis is a key process that allows nutrient uptake and cellular trafficking and is co-opted in cancer to enable tumor growth and metastasis. Recently, extracellular vesicles (EVs) have been shown to promote angiogenesis; however, it is unclear what unique features EVs contribute to the process. Here, we studied the role of EVs derived from head and neck squamous cell carcinoma (HNSCC) in driving tumor angiogenesis. Small EVs (SEVs), in the size range of exosomes (50-150 nm), induced angiogenesis both in vitro and in vivo. Proteomic analysis of HNSCC SEVs revealed the cell-cell signaling receptor EPHB2 as a promising candidate cargo to promote angiogenesis. Analysis of patient data further identified EPHB2 overexpression in HNSCC tumors to be associated with poor patient prognosis and tumor angiogenesis, especially in the context of overexpression of the exosome secretion regulator cortactin. Functional experiments revealed that EPHB2 expression in SEVs regulates angiogenesis both in vitro and in vivo and that EPHB2 carried by SEVs stimulates ephrin-B reverse signaling, inducing STAT3 phosphorylation. A STAT3 inhibitor greatly reduced SEV-induced angiogenesis. These data suggest a novel model in which EVs uniquely promote angiogenesis by transporting Eph transmembrane receptors to non-adjacent endothelial cells to induce ephrin reverse signaling.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is an invasive cancer that originates in the oral cavity, larynx, and pharynx, in association with alcohol and tobacco use or exposure to human papillomavirus (1) (2) (3) . While much of the morbidity of HNSCC is caused by local invasion into nerve and vascular tissues of the neck, mortality is driven primarily by metastasis to regional lymph nodes and distant organs (4) (5) (6) (7) . A key event that facilitates this metastasis is tumorassociated lymph and blood vessel formation (Fig. 1A) .
Extracellular vesicles (EVs), including exosomes and other small EVs (SEVs) and larger EVs (LEVs) such as microvesicles, are secreted from cells and mediate cell-cell communication via protein, lipid and nucleic acid cargoes (8) . EVs are key mediators of cellular functions such as survival, proliferation, motility, and apoptosis. Recently, many reports have shown that tumorderived EVs play a large role in tumor progression (9) . Many of these functions are due to paracrine and distant signaling to non-cancer cells, including induction of cancer-associated fibroblasts, regulation of tumor immunity, and premetastatic niche formation.
Among the paracrine activities, a key reported function of tumor EVs is angiogenesis (10) (11) (12) (13) (14) . Tumor-derived EVs may also promote lymphangiogenesis (15, 16) . Despite the number of studies, implicating both RNA (11, 17, 18) and protein (10, 19, 20) cargoes, a clear and universal mechanism has not emerged for the apparently critical role of EVs in angiogenesis. It is also not clear whether the same mechanisms will be used for different types of blood vessels or by different tumor types.
Current angiogenesis therapy focuses on soluble secreted molecules, especially vascular endothelial growth factor (VEGF). However, despite the use of anti-VEGF therapy in some cancers as well as in "wet" age-related macular degeneration (21) (22) (23) (24) (25) , its utility has been more limited than was originally anticipated (26) (27) (28) . Therefore, identifying unique mechanisms of angiogenesis is of interest both biologically and therapeutically. Since EVs constitute a fundamentally different form of carrier, transporting either internal cytoplasmic cargoes or transmembrane or lipid-linked surface molecules, EV-induced angiogenesis is likely to represent a distinct mode of action from VEGF and other soluble pro-angiogenesis mediators.
In this study, we investigated the role of EVs released from HNSCC cells on angiogenesis and lymphangiogenesis (Fig. 1A) . In vivo tumor-associated angiogenesis correlated with the in vitro SEV production rate of several HNSCC cell lines. 
Results

Cellular SEV production correlates with HNSCC tumor-induced angiogenesis.
To investigate the relationship between EVs and tumor angiogenesis, we correlated the rate of in vitro SEV release by 5 HNSCC cell lines with the capacity of those same cell lines to promote in vivo angiogenesis (Fig. 1 ). SEVs were purified by a cushion density gradient method (29) in order to minimize EV aggregation and enhance EV separation from protein aggregates. EV number, size, marker status and morphology were characterized by nanoparticle tracking, Western blot, and transmission electron microscopy analyses in accordance with current guidelines (30) (Suppl. HNSCC cell lines were injected orthotopically into the tongues of nude or syngeneic mice. The tumors were harvested, fixed, and immunostained for the endothelial cell marker CD31. Analysis of CD31 area/tumor area revealed that Detroit 562 and MOC2 tumors had significantly higher blood vessel density than tumors derived from the other cell lines ( Fig. 1B, 1C ). Detroit 562 and MOC2 cells also exhibited higher rates of in vitro SEV secretion ( Fig. 1D ). Comparison of the association between tumor blood vessel density and SEV secretion rate across all the cell lines by linear regression revealed a strong correlation ( Fig. 1E , R squared value = 0.78).
Purified HNSCC SEVs promote endothelial tube formation
To directly test the angiogenesis-promoting effects of HNSCC-derived SEVs, we performed an in vitro tube formation assay. Human umbilical vein endothelial cells (HUVECs) were treated for 12 hours with conditioned medium or EVs purified from 2 different human HNSCC cell lines, OSC19
and Detroit 562, before obtaining phase contrast images for analysis of total tube length and number of junctions. Compared to control media, conditioned medium from HNSCC cells significantly increased endothelial tube network formation. By contrast, conditioned medium that was depleted of EVs by ultracentrifugation for 2 hours at 100,000 x g did not increase tube formation over that of control media (Fig. 1F ). Finally, the addition of purified HNSCC SEVs to the control medium induced formation of a significantly more extensive tube network ( Fig. 1F ). We tested two concentrations of SEVs, 5 x 10 7 -which we estimate to be approximately the number of SEVs contained in the 400 µl of OSC19 conditioned medium used in the assay -and 1x10 8 , which had slightly increased efficacy for Detroit 562 EVs but not for OSC19 EVs. In contrast, LEVs at the same concentrations did not affect tube formation (Suppl. Fig. 2A ). Purified SEVs from 2 other HNSCC cell lines also induced HUVEC tube formation, suggesting that this is a common property of HNSCC EVs (Suppl. Fig. 2B ). To examine the effects of HNSCC-derived EVs on lymphangiogenesis, we performed the same assay using lymphatic endothelial cells (HMVEC-6 dLyAds). HNSCC-conditioned medium as well as HNSCC-derived SEVs, but not EV-depleted conditioned medium, facilitated tube network and junction formation in HMVEC-dLyAds similarly to that of HUVECs (Suppl. Fig. 2C ).
Proteomics and transcriptomics analysis identifies EPHB2 as a candidate angiogenic EV cargo
To determine whether HNSCC SEVs carry angiogenic proteins, we performed proteomic analysis of SEVs purified from 3 different human HNSCC cell lines. One of the datasets was published previously for SEVs from SCC61 cells (31) . In addition, we performed proteomics analyses on SEVs purified by cushion density gradient ultracentrifugation from OSC19 and Detroit 562 cells, identifying respectively 1016 and 1237 unique proteins (Suppl. Table 1 , 2). From these three datasets, we identified a number of proteins that have been shown to regulate angiogenesis and/or lymphangiogenesis (Table 1) . Notably, multiple ephrin and ephrin receptor (Eph) family proteins were detected, suggesting that this class of proteins could drive angiogenesis in HNSCC tumors. Furthermore, EPHB2 and EPHA2 were detected in all three HNSCC SEV samples (Table 1) .
To prioritize our results, we analyzed publicly available RNA-Seq data for HNSCC patient tumors in the TCGA database to determine whether RNA expression levels of EPHB2 or EPHA2 correlate with patient outcome. This analysis revealed that overexpression of EPHB2 -but not EPHA2 -significantly correlates with decreased survival of HNSCC patients ( Fig. 2A ). EPHB2 is also an interesting cargo, since it can promote ephrin-B reverse signaling (53, 54) and studies in genetically engineered mouse models have shown that ephrin-B reverse signaling plays a critical role in both developmental and tumor angiogenesis (32, 55, 56) . In addition, further analysis of the TCGA RNA-Seq data using gene set enrichment analysis revealed that the Hallmark Angiogenesis gene set is closely correlated with EPHB2 mRNA expression in HNSCC patient tumors ( Fig. 2B ).
We previously showed that the HNSCC-overexpressed protein cortactin promotes exosome secretion (31) . Cortactin overexpression had been previously found in small datasets to correlate with poor patient prognosis (57) (58) (59) . Analysis using the TCGA RNA-Seq dataset confirmed that cortactin overexpression significantly correlates with decreased survival of HNSCC patients ( Fig. 2C ). Based on these data, we hypothesized that key exosome cargoes might synergize with cortactin overexpression to drive poor patient prognosis. Indeed, analysis of TCGA RNA-Seq data revealed that co-overexpression of cortactin with EPHB2 further stratified patients into a subset with greatly decreased survival, compared with patient tumors with overexpression of only cortactin, only EPHB2, or no overexpression of either gene ( Fig. 2D and   7 Suppl. Table 3 ). Conversely, analysis of the relationship between cortactin and EPHB2 expression with the Hallmark Angiogenesis gene set revealed that only EPHB2 expression correlated with expression of genes in that gene set ( Fig. 2D ). These data are consistent with cortactin as a general regulator of exosome secretion and EPHB2 as a specific angiogenic cargo.
Immunofluorescent analysis of a tissue microarray with HNSCC samples from 103 patients further revealed that EPHB2 and cortactin co-overexpression is closely related to regional lymph node and distant organ metastasis, especially for undifferentiated tumors ( Fig. 2E and Suppl. Fig. 3 ).
Based on these data, we focused on EPHB2 as a promising candidate to test for its role in SEVmediated angiogenesis.
EPHB2 in SEVs promotes endothelial tube formation
In Western blot analyses, EPHB2 protein was expressed in SEVs from multiple human HNSCC cell lines ( Fig. 3A ). As it was expressed at the highest levels in OSC19 cells, we focused on this cell line for most further mechanistic studies. Consistent with the ability of OSC19 SEVs but not LEVs to induce tube formation, we detected very little EPHB2 expression in LEVs in comparison to SEVs (Fig. 3A ). EPHB2 can induce angiogenesis by binding to B-type ephrins on endothelial cells and inducing ephrin reverse signaling, a process that is thought to require cell-cell contacts (32, 55) . We hypothesized that SEVs could substitute for neighboring cells and induce ephrin reverse signaling at a distance. To test this possibility, we examined phosphorylation of ephrin-B in HUVECs after incubation with OSC19 SEVs. As a positive control, we added recombinant EPHB2 (Fc-EPHB2). As shown in Fig. 3B , both Fc-EPHB2 and purified OSC19 SEVs induced ephrin-B phosphorylation in HUVECs, compared to no treatment control. To test the role of SEVassociated EPHB2 in angiogenesis, we blocked the ability of EPHB2 to bind to ephrin-B ligands on cells by preincubating the OSC19 SEVs with recombinant ephrin-B2 protein (Fc-ephrin-B2) for 10 minutes before adding the mixture to endothelial cells (see schema in Fig. 3C ). Compared to control SEVs, uptake of SEVs preincubated with Fc-ephrin-B2 by HUVEC cells was decreased (Suppl. Fig. 4 ), suggesting that EPHB2-ephrinB interactions mediate binding of a subset of SEVs with cells. Likewise, preincubation of Fc-ephrin-B2 with SEVs reduced their ability to induce HUVEC tube formation in a dose-dependent manner ( Fig. 3D ). A similar result was observed using SEVs purified from Detroit 562 cells ( Fig. 3D ). Recombinant Fc-ephrin-B2 protein alone had only a small effect in the opposite direction at the highest concentration.
We also tested the effect of SEVs purified from EPHB2-knockdown (KD) or EPHB2overexpressed (OE) OSC19 cells on angiogenesis. Similar to the results with Fc-ephrin-B2 blocking of EPHB2 on SEVs, tube formation of HUVECs treated with EPHB2-KD SEVs was significantly reduced compared to those treated with control SEVs (Fig. 4A, B ). Conversely, 8 EPHB2-OE SEVs increased HUVEC tube formation ( Fig. 4C, D) . The enhanced tube formation by EPHB2-OE SEVs was statistically significant compared to control SEVs when a lower number of SEVs (2.5x10 7 ) was used as opposed to the higher number (5x10 7 ) used in the other tube formation assays. These data indicate that both the number and EPHB2 cargo content of SEVs impact endothelial tube formation.
HNSCC-derived EVs induce in vivo angiogenesis
To test the role of EV-delivered EPHB2 in in vivo angiogenesis, we performed a Matrigel plug assay (60) (61) (62) in which SEVs purified from OSC19 cells were mixed with growth factor reduced Matrigel and implanted subcutaneously in nude mice. After 21 days, the plugs were harvested and analyzed for blood vessel content ( Fig 4E) . Quantitation of CD31-positive vessel area/image area in the plugs showed that control EVs induced blood vessel formation. By contrast, in the absence of EVs or in the presence of EPHB2-KD or Fc-ephrin-B2-pretreated EVs, very few blood vessels were formed ( Fig. 4E ). We validated that the Matrigel plugs indeed contained blood vessels by Hematoxylin and Eosin staining as well as co-staining of some samples for both CD31 and hemoglobin (Suppl. Fig 5A) .
To determine whether EPHB2 expression in HNSCC tumors regulates angiogenesis, we injected OSC19 cells into the tongues of nude mice. While there was no effect of EPHB2 expression on tumor size, the vessel density in EPHB2-OE OSC19 tumors was significantly increased compared with control and EPHB2-KD tumors ( Fig. 4F ). EPHB2-KD did not lead to reduced angiogenesis in OSC19 tumors, possibly due to the relatively low basal level of angiogenesis in this cell line ( Fig 1E) . Indeed, when we assessed angiogenesis in Detroit 562 tumors that have higher baseline levels of angiogenesis and higher SEV secretion rates ( Fig 1E) , EPHB2-KD reduced angiogenesis (Suppl. Fig. 5B ). In addition, EPHB2-OE in Detroit 562 cells led to enhanced tumor blood vessel density (Suppl. Fig. 5B ). Although OSC19 is not a metastatic cell line in this model, we analyzed lymph nodes from these mice. We observed one mouse with lymph node metastasis in the EPHB2-OE tumor group, but no metastasis from the other groups ( Fig. 4G ). For the Detroit 562 cells, KD or OE of EPHB2 respectively decreased and increased the percent of mice with lymph node metastases; however the differences were not statistically significant (Suppl. Fig. 5C ).
miRNAs are not responsible for HNSCC SEV-mediated angiogenesis
A number of reports have implicated miRNAs as EV cargoes regulating angiogenesis (17, 18, 63) .
In addition to inducing ephrin reverse signaling, EPHB2 on SEVs could potentially drive angiogenesis by enhancing binding and uptake of SEVs by target cells, to deliver miRNAs. To 9 determine whether miRNAs are part of the EV-driven angiogenesis we observed, we inhibited miRNA maturation in OSC19 cells by depletion of DICER with shRNA (Suppl. Fig. 6A ) and purified SEVs from those cells. To confirm the effect of DICER-depletion on the levels of mature miRNAs in SEVs, we quantitated total RNA as well as candidate mature and pre-miRNA levels in SEVs purified from control and DICER-KD cells. For candidate miRNAs, we chose miR-155 and miR-21, based on their known expression in HNSCC (64, 65) and their previous association with angiogenesis (66, 67) . Consistent with the >90 % KD of DICER in cells (Suppl. Fig. 6A ), mature miRNA was decreased and pre-miRNA was increased in EVs purified from DICER-KD cells (Suppl. Fig. 6B ). Analysis of the total tube length and numbers of junctions of HUVECs treated with EVs from DICER-KD cells did not show significant changes compared to that of HUVECs treated with control EVs (Suppl. Fig. 6C ). These data suggest that delivery of miRNA is unlikely to be the mechanism by which EPHB2 on HNSCC SEVs promotes angiogenesis.
EV-carried EPHB2 promotes angiogenesis by inducing ephrin reverse signaling.
Our initial characterization of OSC19 SEVs showed that they can induce ephrin-B phosphorylation ( which is known to be stimulated by ephrin-B reverse signaling (68) was also increased by SEVs in an EPHB2-dependent manner ( Fig. 5A ). Interestingly, phosphorylation of VEGFR2 was not increased by SEV treatment (Fig. 5A ). Since STAT3 phosphorylation was strongly induced by SEVs, dependent on their EPHB2 content, we tested whether inhibition of STAT3 affects SEVinduced tube formation. Indeed, inhibition with the small molecule inhibitor Stattic (69) greatly reduced both tube length and junction number (Fig. 5B ). These data indicate that EPHB2 carried on SEVs induces angiogenesis by activation of ephrin reverse signaling and downstream STAT3 activation.
Discussion
In this study, we found that a key Eph receptor is exported in HNSCC SEVs and drives tumor- can induce signaling at a distance to recruit blood vessels into tumors, where they facilitate tumor survival and metastasis (Fig. 5C ).
Our model, in which key transmembrane or membrane-linked molecules are transported by EVs, may help to explain the unique role that EVs appear to play in driving angiogenesis. Thus, EVtransported membrane-linked molecules could synergize with soluble, diffusible secreted factors.
For example, ephrin-B reverse signaling is known to synergize with VEGF signaling, but traditional models would limit Eph-ephrin signaling to cell-cell contacts. By contrast, EVs secreted from the center of a hypoxic tumor could reach the tumor edge and beyond to stimulate angiogenic sprouting towards the source of secreted factors. Gradients of EVs could provide stable cues that synergize with soluble angiogenic factors such as VEGFs or angiopoietins.
Previous studies have also shown that EVs derived from both cancer and normal cells (including mesenchymal stem cells, fibroblasts, microglia, and endothelial progenitor cells) play a key role in angiogenesis (70) (71) (72) (73) . Some previously reported angiogenic protein EV cargoes include IL-8, IGFBP1, IGFBP3, carbonic anhydrase 9, annexin II, myoferlin, WNT4, VEGFA and VEGFD (13, 19, 20, (74) (75) (76) . From our proteomics analysis of HNSCC EVs, IL-8, IGFBP1, carbonic anhydrase 9, WNT4, and VEGFR were not observed (Table 1) . VEGFA, VEGFC, IGFBP3, Annexin II and myoferlin were observed in at least one HNSCC EV sample, and VEGFA and IGFBP3 have been previously reported to promote angiogenesis in HNSCC (77, 78) . In this manuscript, we focused on receptor-ligand transmembrane molecules that could not be transported in any other way than via EVs and that could specifically target the EVs to endothelial cells. Furthermore, in separate antibody array experiments, we did not observe significant amounts of VEGFs or IGFBP3 associated with HNSCC SEVs (not shown), suggesting that only minimal amounts associate with SEVs or that they are lost during our purification process. However, it is certainly possible that additional EV cargoes may promote angiogenesis in HNSCC tumors and some cytoplasmic cargoes could even be carried in the same vesicles as Ephrin receptors and ligands.
In addition to protein cargoes, a number of EV-derived miRNAs have been shown to promote angiogenesis (9, 79) . Using DICER-KD to prevent maturation of pre-miRNAs in HNSCC cells, we detected no effect of KD EVs on endothelial tube formation. While our result does not rule out EV-delivered miRNAs being important angiogenic regulators in other systems, it does suggest that it is not a major driver in our system. Eph receptors are a subfamily of receptor protein-tyrosine kinases (80) and were first identified as regulators of cell-cell interactions in the nervous system (81, 82), including axon guidance and branching, and development of neuronal growth cones. More recently, knockout mouse studies identified EphB-ephrin-B signaling as a key regulatory control for development of blood and lymph vessels, due to interactions between EPHB4 and ephrin-B2 on venous and arterial endothelial cells, respectively (32, 55) . In one of those studies, ephrin-B reverse signaling was also shown to be important for tumor angiogenesis (55) . Additional EphB receptors, including EPHB2, may act in a similar manner in remodeling the embryonic vascular system (34) .
Ephrins are also involved in cell migration, cell fate, and immunity (83, 84) .
Our study is the first to our knowledge to identify a role for EphB-ephrin-B interactions in HNSCC-induced tumor angiogenesis. Furthermore, our study is the first to identify Ephrin family molecules on EVs as key angiogenesis regulators. Consistent with our finding that SEVs can induce ephrin reverse signaling in endothelial cells, a recent study showed that exosomal EPHB2ephrin-B1 reverse signaling can induce neuronal repulsion (85) . These results suggest that EVbased ephrin signaling may be a general paradigm that could mediate ephrin signaling in a variety of contexts, including axon guidance, angiogenesis, and potentially immune cell interactions (86) (87) (88) (89) .
Consistent with our TCGA analysis ( Fig. 2A) , EPHB2 overexpression in several other cancer types has been reported to correlate with decreased patient survival (90, 91) . We further found that the correlation of EPHB2 overexpression in HNSCC tumors with poor prognosis was even higher if the exosome secretion regulator cortactin (31) was also overexpressed, suggesting that exosomal EPHB2 may drive tumor aggressiveness. Our findings suggest that induction of tumor angiogenesis could be an important component of that process. Future studies should further elucidate the role of EV-carried EPHB2 and other EV-associated Ephrin family molecules in driving near and long distance signaling in cancer.
Anti-angiogenesis therapy has thus far been employed in a subset of cancers and largely consists of anti-VEGF antibody or kinase inhibitor therapy against VEGFR signaling (22, (92) (93) (94) (95) (96) (97) (98) .
In HNSCC, a number of trials testing anti-angiogenesis therapies are either completed or ongoing; however, the effects have been limited (99) (100) (101) (102) (103) (104) . In the most recent phase 3 trial, conventional therapy with the monoclonal anti-VEGF antibody bevacizumab did not show significant improvement in overall or disease-free survival compared to conventional therapy alone (105) . In fact, in the latest national comprehensive cancer network guidelines for HNSCC therapy, no anti-VEGF reagents were recommended (106), despite strong association of numerous angiogenesis regulators with poor prognosis in HNSCC (107, 108) . These data suggest that new targets are needed. One possibility is to test whether EV-based targets such as EPHB receptors or ligands that should synergize with VEGF would lead to greater efficacy.
In summary, we find that EPHB2 carried on HNSCC-secreted EVs can induce ephrin-B reverse signaling and tumor angiogenesis. This mechanism may be important for understanding of the HNSCC microenvironment and may also be a potential target for future cancer therapy. 
Methods
Antibodies
Isolation of EVs from conditioned medium and EV characterization
Cells were cultured to 80% confluence, and washed with PBS before culturing for 48 h in Opti-MEM, which is a serum-free but growth factor-containing medium. Conditioned medium was subjected to serial centrifugation to respectively sediment live cells (300 x g for 5 min), dead cells (2,500 x g for 25 min), and LEVs (10,000 x g for 30 min in Ti 45 rotor). To obtain SEVs, we used a cushion-density gradient protocol (29 were collected and diluted in PBS before pelleting through another round of centrifugation at 100,000 x g for 3 h, followed by washing and resuspension in PBS.
Analysis of size and protein concentration of EVs
All EV preparations were analyzed for size and concentration by nanoparticle tracking with a Zetaview analyzer (Particle Metrix GmbH, Meerbusch, Germany) as recommended by the company. EV protein levels were determined using the microBCA Protein Assay Reagent kit (Pierce) according to the manufacturer's instructions. 
Transmission electron microscopy analysis
Orthotopic nude mouse model of HNSCC
We used an orthotopic nude mouse model of HNSCC (109, 110) . 
Assessment of blood vessel density from tumor tissue
in the tumors was calculated using ImageJ. CD31 stained area / whole tumor area x 100 was assessed as blood vessel density.
Matrigel plug assay
The Matrigel plug assay was performed essentially as previously described (61) . Briefly, growth factor-reduced Matrigel (350 μl) was mixed in liquid form at 4℃ with 50 μl of EVs (30 μg). The
Matrigel-SEV mixture was injected subcutaneously into the flanks of 6 to 8-week-old athymic nude mice. After 21 days, mice were sacrificed and the Matrigel plugs were excised and fixed in 4% formaldehyde in phosphate buffer. Plugs were embedded in paraffin, sectioned, and immunostained for CD31. Images were acquired with an A1R Confocal laser Microscope system (Nikon) equipped with a × 20/1.40 NA Plan Apo objective lens (Nikon), and analyzed using ImageJ.
Tumor tissue microarray
After appropriate institutional review board approval for retrospective study of patient specimens and records, a tissue microarray (TMA) of 120 primary oral cavity SCCs was created from previously untreated patients with no history of prior cancer. After creation of the array, patient identifiers were purged so the specimens were deidentified. The array was assembled retrospectively from 1997 to 2011 from patients from databases from the Departments of 
Mass spectrometry and liquid chromatography MS/MS analysis
Shotgun proteomic analysis of purified EVs was performed by first partially resolving the proteins by about 1.5 cm in a 10% Novex precast gel, excising the protein region, and then performing ingel tryptic digestion to recover peptides. The peptides were analyzed via Multidimensional Protein Identification Technology essentially as described earlier (112, 113) . Briefly, digested peptides were loaded onto a biphasic pre-column consisting of 4 cm of reversed phase material followed against the human protein database to which common contaminants had been appended using Sequest (114) and identifications were collated and filtered using Scaffold (www.proteomesoftware.com).
Bioinformatic and Statistical analyses
Statistical analysis of overall survival and gene expression was assessed for the Cancer Genome Atlas (TCGA) patient data using Linkedomics (115) (http://linkedomics.zhang-lab.org/admin.php).
Single-sample Gene set enrichment analysis (ssGSEA) was performed on RNA-seq data of HNSCC patients from TCGA database using from Msigdb hallmark angiogenesis gene set (116) .
List of the gene set was shown in Supplementary 
Study Approval
Animal procedures were carried out according to a protocol approved by The Vanderbilt (55), we did not detect changes due to SEV treatment, suggesting selective activation of ephrin reverse signaling pathways by SEVs. 
